TY - JOUR
T1 - Prenatal diethylstilbestrol exposure and mammographic density
AU - Strohsnitter, William C.
AU - Bertrand, Kimberly A.
AU - Troisi, Rebecca
AU - Scott, Christopher G.
AU - Cheville, Andrea L.
AU - Hoover, Robert N.
AU - Palmer, Julie R.
AU - Vachon, Celine M.
N1 - Funding Information:
1Department of Molecular, Cell, and Cancer Biology, University of Massachusetts Medical School, Worcester, MA 2Slone Epidemiology Center at Boston University, Boston, MA 3Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, MD 4Department of Health Sciences Research, Mayo Clinic, Rochester, MN 5Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, MN
Funding Information:
Key words: diethylstilbestrol, prenatal exposure, breast density, prospective study Abbreviations: DES: Diethylstilbestrol; BI-RADS: Breast Imaging Reporting and Data System; OR: Odds ratios; CI: Confidence Interval; BMI: Body Mass Index; BPA: Bisphenol A; E2: Estradiol; NCI: National Cancer Institute Disclosures: None of the authors has any conflicts of interest to declare. Grant sponsor: National Cancer Institute; Grant number: HHSN261201500029C (to WCS), HHSN261201500026C (to JRP); Grant sponsor: Dahod Breast Cancer Research Program at the Boston University School of Medicine (to K.A.B.) DOI: 10.1002/ijc.31524 History: Received 7 July 2017; Accepted 26 Mar 2018; Online 15 Apr 2018 Correspondence to: William C. Strohsnitter, DSc, Department of Molecular, Cell, and Cancer Biology, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, Tel.: 5088565027, Fax: 508-856-2212, E-mail: william.strohsnitter@umassmed.edu
Publisher Copyright:
© 2018 UICC
PY - 2018/9/15
Y1 - 2018/9/15
N2 - In a prospective cohort study of the health effects associated with prenatal Diethylstilbestrol (DES) exposure, DES was associated with an increased breast cancer risk after 40 years of age. It is unknown whether it is associated with greater mammographic density, which strongly predicts breast cancer risk. A cohort of DES-exposed and unexposed women was assembled at the Mayo Clinic in 1975, and followed through 2012 as part of the National Cancer Institute's DES follow-up study. Mammographic density from 3,637 mammograms for 332 (222 DES-exposed, 110 unexposed) women in this cohort screened at the Mayo Clinic, Rochester between 1996 and 2015 was determined clinically using the Breast Imaging Reporting and Data System (BI-RADS). Any effect of prenatal DES exposure on mammographic density was estimated using repeated measures logistic regression. There was no association between prenatal DES exposure and high mammographic density for either premenopausal [Odds ratios (OR) = 0.92 (95% Confidence Interval (CI): 0.50, 1.7] or postmenopausal women (OR = 0.90; 95% CI: 0.54, 1.5). Among premenopausal women, associations differed by body mass index (BMI), with ORs of 1.47 (0.70, 3.1) for women with BMI above the median and 0.53 (0.23, 1.3) for those with BMI below the median (pinteraction = 0.05). Overall, however, prenatal DES exposure was not associated with high mammographic density in this sample of DES Study participants. Consequently, this study does not provide evidence that high mammographic density is involved with the influence of DES on breast cancer risk.
AB - In a prospective cohort study of the health effects associated with prenatal Diethylstilbestrol (DES) exposure, DES was associated with an increased breast cancer risk after 40 years of age. It is unknown whether it is associated with greater mammographic density, which strongly predicts breast cancer risk. A cohort of DES-exposed and unexposed women was assembled at the Mayo Clinic in 1975, and followed through 2012 as part of the National Cancer Institute's DES follow-up study. Mammographic density from 3,637 mammograms for 332 (222 DES-exposed, 110 unexposed) women in this cohort screened at the Mayo Clinic, Rochester between 1996 and 2015 was determined clinically using the Breast Imaging Reporting and Data System (BI-RADS). Any effect of prenatal DES exposure on mammographic density was estimated using repeated measures logistic regression. There was no association between prenatal DES exposure and high mammographic density for either premenopausal [Odds ratios (OR) = 0.92 (95% Confidence Interval (CI): 0.50, 1.7] or postmenopausal women (OR = 0.90; 95% CI: 0.54, 1.5). Among premenopausal women, associations differed by body mass index (BMI), with ORs of 1.47 (0.70, 3.1) for women with BMI above the median and 0.53 (0.23, 1.3) for those with BMI below the median (pinteraction = 0.05). Overall, however, prenatal DES exposure was not associated with high mammographic density in this sample of DES Study participants. Consequently, this study does not provide evidence that high mammographic density is involved with the influence of DES on breast cancer risk.
KW - breast density, prospective study
KW - diethylstilbestrol
KW - prenatal exposure
UR - http://www.scopus.com/inward/record.url?scp=85046252796&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046252796&partnerID=8YFLogxK
U2 - 10.1002/ijc.31524
DO - 10.1002/ijc.31524
M3 - Article
C2 - 29658110
AN - SCOPUS:85046252796
SN - 0020-7136
VL - 143
SP - 1374
EP - 1378
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 6
ER -